Single cell technologies for drug discovery

HiFiBiO Therapeutics is at the forefront of developing innovative immunotherapies through its proprietary Drug Intelligence Science (DIS®) platform. This platform integrates advanced single-cell technology with artificial intelligence and machine learning analytics to enhance the understanding of cellular pathology across various diseases. By leveraging DIS®, HiFiBiO aims to identify predictive biomarkers, discover new therapeutic targets, and select antibodies more effectively, ultimately improving clinical outcomes for patients with significant unmet medical needs. The platform's capabilities allow for comprehensive data analysis, including imaging, sequencing, and pharmacokinetics, which are crucial for guiding clinical trial designs and patient stratification.

The company is actively advancing a pipeline of next-generation immunotherapies targeting cancer and immunology/inflammation diseases. Their current clinical programs include several monoclonal antibodies, such as the first-in-class TNFR2 agonist HFB200301 and the next-generation OX40 agonist HFB301001. HiFiBiO's approach emphasizes the importance of understanding immune modulation and the tumor microenvironment, utilizing their DIS® platform to drive the discovery and development of therapeutics that can effectively address complex disease mechanisms. Through collaborations and partnerships, HiFiBiO is committed to accelerating the development of these transformative therapies, aiming to deliver significant advancements in patient care.

United States

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For more information, please visit www.hifibio.com.

HiFiBiO Therapeutics

Company Details